Optimization of IV Ketamine for Treatment Resistant Depression
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT00768430 |
Recruitment Status :
Completed
First Posted : October 8, 2008
Results First Posted : January 31, 2014
Last Update Posted : January 31, 2014
|
- Study Details
- Tabular View
- Study Results
- Disclaimer
- How to Read a Study Record
Tracking Information | |||||||
---|---|---|---|---|---|---|---|
First Submitted Date ICMJE | October 7, 2008 | ||||||
First Posted Date ICMJE | October 8, 2008 | ||||||
Results First Submitted Date ICMJE | September 5, 2013 | ||||||
Results First Posted Date ICMJE | January 31, 2014 | ||||||
Last Update Posted Date | January 31, 2014 | ||||||
Study Start Date ICMJE | November 2008 | ||||||
Actual Primary Completion Date | September 2012 (Final data collection date for primary outcome measure) | ||||||
Current Primary Outcome Measures ICMJE |
MADRS [ Time Frame: 24 hours post-infusion ] Montgomery-Asberg Depression Rating Scale, each of the ten items can be scored from 0 (absence of symptoms to 6 most severe) and has a total score range of 0-60. A lower score on a MADRS indicates a less severe depression.
|
||||||
Original Primary Outcome Measures ICMJE |
MADRS [ Time Frame: 40 minutes, 120 minutes, 24 hours, 7 days ] | ||||||
Change History | |||||||
Current Secondary Outcome Measures ICMJE | Not Provided | ||||||
Original Secondary Outcome Measures ICMJE | Not Provided | ||||||
Current Other Pre-specified Outcome Measures | Not Provided | ||||||
Original Other Pre-specified Outcome Measures | Not Provided | ||||||
Descriptive Information | |||||||
Brief Title ICMJE | Optimization of IV Ketamine for Treatment Resistant Depression | ||||||
Official Title ICMJE | Optimization of Intravenous Ketamine for Treatment-Resistant Depression: A Randomized, Placebo-Controlled, Triple-masked, Clinical Trial | ||||||
Brief Summary | Existing treatments for major depressive disorder (MDD) generally take weeks to months to exert their maximal benefit. There is an urgent need to develop rapid-acting treatments for MDD. Ketamine, a high-affinity N-methyl-D-aspartate (NMDA) glutamate receptor antagonist, has been used as a standard intravenous (IV) anesthetic agent for many years in both pediatric and adult patients. Beyond its well-established role in anesthesia and pain management, there is emerging evidence that ketamine may have rapid antidepressant properties for patients with severe mood disorders. In this study we are investigating whether ketamine can have an antidepressant effect compared to midazolam. Midazolam has similar anesthetic effects compared to ketamine but has not been shown to be an antidepressant, and is therefore acting as an active control in this study. The study period can last up to 8 weeks, depending on your response to the study medication. There are two required overnight stays in our Research Commons as part of this study. |
||||||
Detailed Description | Not Provided | ||||||
Study Type ICMJE | Interventional | ||||||
Study Phase ICMJE | Phase 2 | ||||||
Study Design ICMJE | Allocation: Randomized Intervention Model: Parallel Assignment Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor) Primary Purpose: Treatment |
||||||
Condition ICMJE |
|
||||||
Intervention ICMJE |
|
||||||
Study Arms ICMJE |
|
||||||
Publications * |
|
||||||
* Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline. |
|||||||
Recruitment Information | |||||||
Recruitment Status ICMJE | Completed | ||||||
Actual Enrollment ICMJE |
73 | ||||||
Original Estimated Enrollment ICMJE |
64 | ||||||
Actual Study Completion Date ICMJE | November 2012 | ||||||
Actual Primary Completion Date | September 2012 (Final data collection date for primary outcome measure) | ||||||
Eligibility Criteria ICMJE | Inclusion Criteria:
Exclusion Criteria:
|
||||||
Sex/Gender ICMJE |
|
||||||
Ages ICMJE | 21 Years to 80 Years (Adult, Older Adult) | ||||||
Accepts Healthy Volunteers ICMJE | No | ||||||
Contacts ICMJE | Contact information is only displayed when the study is recruiting subjects | ||||||
Listed Location Countries ICMJE | United States | ||||||
Removed Location Countries | |||||||
Administrative Information | |||||||
NCT Number ICMJE | NCT00768430 | ||||||
Other Study ID Numbers ICMJE | GCO 07-0114 | ||||||
Has Data Monitoring Committee | Yes | ||||||
U.S. FDA-regulated Product | Not Provided | ||||||
IPD Sharing Statement ICMJE | Not Provided | ||||||
Current Responsible Party | Sanjay Johan Mathew, Baylor College of Medicine | ||||||
Original Responsible Party | Sanjay Mathew, MD, Mount Sinai School of Medicine | ||||||
Current Study Sponsor ICMJE | Baylor College of Medicine | ||||||
Original Study Sponsor ICMJE | Icahn School of Medicine at Mount Sinai | ||||||
Collaborators ICMJE | Icahn School of Medicine at Mount Sinai | ||||||
Investigators ICMJE |
|
||||||
PRS Account | Baylor College of Medicine | ||||||
Verification Date | December 2013 | ||||||
ICMJE Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP |